NMR-based lipidomic analysis of blood lipoproteins differentiates the progression of coronary heart disease
- PMID: 24689886
- DOI: 10.1021/pr500061n
NMR-based lipidomic analysis of blood lipoproteins differentiates the progression of coronary heart disease
Abstract
Abnormal lipid composition and metabolism of plasma lipoproteins play a crucial role in the pathogenesis of coronary heart disease (CHD). A (1)H NMR-based lipidomic approach was used to investigate the correlation of coronary artery stenosis with the atherogenic (non-HDL) and atheroprotective (HDL) lipid profiles in 99 patients with CHD of various stages of disease and compared with 60 patients with normal coronary arteries (NCA), all documented in coronary angiography. The pattern recognition models created from lipid profiles predicted the presence of CHD with a sensitivity of 87% and a specificity of 88% in the HDL model and with 90% and 89% in the non-HDL model, respectively. Patients with mild, moderate, and severe coronary artery stenosis were progressively differentiated from those with NCA in the non-HDL model with a statistically significant separation of severe stage from both mild and moderate. In the HDL model, the progressive differentiation of the disease stages was statistically significant only between patients with mild and severe coronary artery stenosis. The lipid constituents of lipoproteins that mainly characterized the initial stages and then the progression of the disease were the high levels of saturated fatty acids in lipids in both HDL and non-HDL particles, the low levels of HDL-phosphatidylcholine, HDL-sphingomyelin, and omega-3 fatty acids and linoleic acid in lipids in non-HDL particles. The conventional lipid marker, total cholesterol, found in low levels in HDL and in high levels in non-HDL, also contributed to the onset of the disease but with a much lower coefficient of significance. (1)H NMR-based lipidomic analysis of atherogenic and atheroprotective lipoproteins could contribute to the early evaluation of the onset of coronary artery disease and possibly to the establishment of an appropriate therapeutic option.
Similar articles
-
Evaluation of established coronary heart disease on the basis of HDL and non-HDL NMR lipid profiling.J Proteome Res. 2010 Feb 5;9(2):897-911. doi: 10.1021/pr900783x. J Proteome Res. 2010. PMID: 20020777
-
Analysis of the composition of plasma lipoproteins in patients with extensive coronary heart disease using 1H NMR spectroscopy.Hellenic J Cardiol. 2008 Mar-Apr;49(2):72-8. Hellenic J Cardiol. 2008. PMID: 18459463
-
NMR-Based Lipid Profiling of High Density Lipoprotein Particles in Healthy Subjects with Low, Normal, and Elevated HDL-Cholesterol.J Proteome Res. 2017 Apr 7;16(4):1605-1616. doi: 10.1021/acs.jproteome.6b00975. Epub 2017 Mar 21. J Proteome Res. 2017. PMID: 28287268
-
High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease.Cardiovasc Res. 2014 Aug 1;103(3):350-61. doi: 10.1093/cvr/cvu139. Epub 2014 Jun 15. Cardiovasc Res. 2014. PMID: 24935432 Review.
-
HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis.Atherosclerosis. 2010 Jan;208(1):3-9. doi: 10.1016/j.atherosclerosis.2009.05.034. Epub 2009 Jun 6. Atherosclerosis. 2010. PMID: 19595353 Review.
Cited by
-
The Effects of Calculated Remnant-Like Particle Cholesterol on Incident Cardiovascular Disease: Insights from a General Chinese Population.J Clin Med. 2021 Jul 30;10(15):3388. doi: 10.3390/jcm10153388. J Clin Med. 2021. PMID: 34362168 Free PMC article.
-
High Resolution NMR Spectroscopy as a Structural and Analytical Tool for Unsaturated Lipids in Solution.Molecules. 2017 Oct 5;22(10):1663. doi: 10.3390/molecules22101663. Molecules. 2017. PMID: 28981459 Free PMC article. Review.
-
Emerging Biomarkers and Determinants of Lipoprotein Profiles to Predict CVD Risk: Implications for Precision Nutrition.Nutrients. 2024 Dec 27;17(1):42. doi: 10.3390/nu17010042. Nutrients. 2024. PMID: 39796476 Free PMC article. Review.
-
Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics.Diagnostics (Basel). 2023 Feb 15;13(4):721. doi: 10.3390/diagnostics13040721. Diagnostics (Basel). 2023. PMID: 36832218 Free PMC article. Review.
-
Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges.Int J Mol Sci. 2023 Feb 7;24(4):3291. doi: 10.3390/ijms24043291. Int J Mol Sci. 2023. PMID: 36834701 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources